Use of Autologous Serum in the Treatment of Ocular Surface Disorders

Therapeutic outcomes of combined topical autologous serum eye drops with silicone–hydrogel soft contact lenses in the treatment of corneal persistent epithelial defects: A preliminary study

“…The first application of ASEs for the treatment of ocular disease can be traced back to at least 1975 [7], and the first documented successful treatment in patients was for keratoconjunctivitis sicca in 1984 [1,15]. Over the years, topical autologous serum has been used clinically as a topical in vivo medication for treating ocular surface disorders, such as recurrent corneal erosions [16], persistent epithelial defects [8,9,17,18], superior limbic keratoconjunctivitis [11], neurotrophic keratopathy [14], and dry eyes [12,13].…”

“…In some countries it involves patients travelling long distances and makes it difficult for its widespread use. Furthermore, autologous serum eye drops can be expensive in some countries [15]. Further efforts are still needed to solve these problems for these patients worldwide.…”

“…Bandage contact lenses (BCLs), especially siliconehydrogel soft contact lenses (SCLs) with high oxygen permeability and transmissibility, are useful for treating PEDs [3][4][5][6]. Over the past several years, autologous serum eye drops (ASEs) are gaining popular and widespread acceptance as adjuvant therapy for various ocular surface disorders, including PEDs recalcitrant to standard medical therapies [7][8][9][10][11][12][13][14][15][16][17][18]. The combination of BCLs and ASEs for PEDs treatment have also been reported with satisfactory results in a few small series' of PED patients [3,4,6].…”

Treating severe keratoconjunctivitis sicca

“…Данный факт препятствует использованию аутосыворо-ток у таких больных. Более того, приготовление аутосыво-ротки требует специальной подготовки и особых условий ее хранения, что несет в себе риск инфицирования, огра-ничивая ее использование в лечении тяжелых форм СКК [39].…”

Contamination Risk of 100% Autologous Serum Eye Drops in Management of Ocular Surface Diseases

“…A utologous serum eye drops have been studied for the treatment of ocular surface diseases, such as persistent epithelial defects, dry eyes, recurrent corneal erosions, and neurotrophic keratopathy. [1][2][3][4][5][6] Usually, a nonpreserved preparation is preferred to reduce the risk of chemical toxicity, making possible contamination-induced ocular infection a risk. [7][8][9] We conducted a prospective descriptive study to evaluate the sterility (laboratory culture of the eye drops) and safety (clinical evidence of ocular infection) of 100% nonpreserved, autologous, serum eye drop treatment for patients with ocular surface diseases.…”